A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 16, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

April 30, 2027

Conditions
Solid Tumor
Interventions
DRUG

TL118 Capsule

Oral administration

Trial Locations (19)

75251

RECRUITING

Texas Oncology, Dallas

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

91206

RECRUITING

Adventist Health Glendale, Glendale

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Peking University School and Hospital of Stomatology, Beijing

RECRUITING

Chongqing University Cancer Hospital, Chongqing

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou

RECRUITING

Harbin medical university cancer hospital, Harbin

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Jiangxi Cancer Hospital, Nanchang

RECRUITING

Shanxi Cancer Hospital, Xi'an

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

Shanghai East Hospital, Shanghai

RECRUITING

West China Hospital of Sichuan University, Chengdu

RECRUITING

Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Teligene US

INDUSTRY